ライフサイエンスコーパス: long-term survivor

1 There was only one morbid long-term survivor.

2 Alloantibodies were detected in only one long-term survivor.

3 No patient with a score of 5 was a long-term survivor.

4 h high levels of MDR-1 mRNA expression was a long-term survivor.

5 erm survivors, 3/234 in medium, and 10/76 in long term survivors.

6 l therapies were enumerated and described in long-term survivors.

7 s, reduced AML tumor burden, and resulted in long-term survivors.

8 r in the United States this year will become long-term survivors.

9 newly diagnosed with cancer can expect to be long-term survivors.

10 AML patients (age > 60 years), there are few long-term survivors.

11 NCF is stable or improved in long-term survivors.

12 ortality and diminish the quality of life in long-term survivors.

13 ble to receive HSCT after relapse, some were long-term survivors.

14 s considered palliative, as there are rarely long-term survivors.

15 of additional cancers after radiotherapy in long-term survivors.

16 urrent treatment has a detrimental effect on long-term survivors.

17 ultimodality treatment regime, may result in long-term survivors.

18 s/minimize late effects of cancer therapy in long-term survivors.

19 lymphoma showed cancer cells eradication and long-term survivors.

20 ents with T-cell lymphoblastic lymphoma were long-term survivors.

21 peritoneal ovarian carcinoma model with some long-term survivors.

22 and radiation therapy, most patients become long-term survivors.

23 pact on dyspepsia related quality of life in long-term survivors.

24 mes affect a substantial proportion of these long-term survivors.

25 slight survival advantage, but there were no long-term survivors.

26 % of the burned children experiencing CA are long-term survivors.

27 or reducing the late effects of therapy for long-term survivors.

28 s of greater than 5 years were identified as long-term survivors.

29 mplete immunologic tolerance and have become long-term survivors.

30 ly variable clinical course, with occasional long-term survivors.

31 ssful in all cases of HLH, but there were no long-term survivors.

32 ception, infection, or GVHD, and five became long-term survivors.

33 rt-term survivors but were seen in 5 (71.4%) long-term survivors.

34 ven alpha-CD3-IT alone or with MP, none were long-term survivors.

35 ion between days 38 to 119, and three became long-term survivors.

36 ats with rapidly progressive FIV disease and long-term survivors.

37 amination of skin, liver, colon, and lung in long-term survivors.

38 l properties of the HIV-1 env genes from six long-term survivors.

39 with rapidly progressive FIV disease than in long-term survivors.

40 More than 80% of all patients are currently long-term survivors.

41 y 40% of younger and 10% of older adults are long-term survivors.

42 oung women with breast cancer has focused on long-term survivors.

43 the bronchiolar airways in all allografts of long-term survivors.

44 of follow-up, there were 2260 deaths and 236 long-term survivors.

45 d to a post-VSLI HCT, and five patients were long-term survivors.

46 f tumor recurrence as well as short-term and long-term survivors.

47 y 40% of younger and 10% of older adults are long-term survivors.

48 often cause disabling neurotoxic effects in long-term survivors.

49 is very poor, with only a rare population of long-term survivors.

50 mmunologic criteria were defined to identify long-term survivors.

51 ung adults diagnosed with cancer will become long-term survivors.

52 02), 39% (40 of 102), and 62% (63 of 102) of long-term survivors.

53 f 92), 16% (15 of 96), and 49% (37 of 76) of long-term survivors.

54 ategies have resulted in a growing number of long-term survivors.

55 There were 340 (81%) long-term survivors, 100 (29%) of whom were interviewed

56 %) among the 670 patients were identified as long-term survivors; 12 were free of disease after nephr

57 All of the long-term survivors (4.9%) had surgery as a component of

58 l, by 2020 there may be up to half a million long-term survivors after allo-HCT worldwide.

59 The number of long-term survivors after hematopoietic stem-cell transp

60 Nine of the long-term survivors after HSCT had disease progression,

61 Long-term survivors after HSCT probably have an increase

62 Osteoporosis is a common complication in long-term survivors after liver transplantation (LTX).

63 These data indicate that the majority of long-term survivors after transplantation for AA during

64 tying and bile reflux are common concerns in long-term survivors after Whipple surgery.

65 In long-term survivors (all animals receiving combination t

66 ma patients exceeds 50%, while there are few long-term survivors among glioblastoma patients.

67 factors that lead to increased mortality in long-term survivors and efforts to reduce those risks.

68 European studies were largely restricted to long-term survivors and included patients from the 1960s

69 of HIV-1 DNA levels was made with a group of long-term survivors and progressors.

70 h compromised the performance status of most long-term survivors and resulted in a relatively high ri

71 oblastoma to build differential networks for long-term survivors and short-term survivors in The Canc

72 the immunological and pathological status of long-term survivors and to define the role of splenectom

73 This suggests that the long-term survivors are not a separate sub-population bu

74 s improved survival in BC modestly, but most long-term survivors are those who have been transplanted

75 nd its potential physiologic significance in long-term survivors are unknown.

76 s received PCI as scheduled in arm B. Eleven long-term survivors (arm A: four; arm B: seven) underwen

77 e years, particularly after bony resections; long-term survivors (beyond 3 years), however, reported

78 cyte reaction responses were positive in the long-term survivors, but all showed clear evidence of sy

79 sted extensively in patients with cancer and long-term survivors, but few exercise studies have evalu

80 ere screened during their annual visits to a long-term survivor clinic using standard neurocognitive

81 ting manifestation of AIDS in 5 (71.4%) of 7 long-term survivors compared with 8 (17.8%) of 45 short-

82 atterns of hospitalization among a cohort of long-term survivors compared with noncancer controls.

83 oparticles (median survival not reached; 80% long-term survivors) compared to cisplatin in convention

84 Within this growing population of long-term survivors, considerable effort has been put fo

85 The functional activity of env clones from long-term survivors D and DH was comparable to that seen

86 Long-term survivors develop histologic changes in the al

87 However, long-term survivors developed a regulatory cell populati

88 Long-term survivors developed specific Th1 splenocyte re

89 vor Study (CCSS), a North American cohort of long-term survivors diagnosed from 1970-1986.

90 Both short- and long-term survivors displayed higher ferritin/transferri

91 In one long-term survivor, donor specific hyporesponsiveness wa

92 In the long-term survivors, donor, but not third party, MHC mat

93 ent often leads to neurologic dysfunction in long-term survivors, emphasizing the need for novel ther

94 hildhood cancer in the last several decades, long-term survivors face considerable morbidity and mort

95 for presumed metastatic progression and are long-term survivors following palliative chemotherapy.

96 hyporesponsiveness was detected in the other long-term survivor for the first 133 days, after which a

97 (P < 0.0001), and furthermore, led to 37% of long-term survivors free of disease.

98 ical predictors that would help discriminate long-term survivors from fatalities.

99 Long-term survivors (G3) showed a significant drop in SU

100 Long-term survivors (G3) showed a significantly differen

101 As the number of long-term survivors grows, identifying and minimizing th

102 with epithelial ovarian cancer, one group of long-term survivors (> 5 years) and one group of short-t

103 to 100% of mice treated with Ad.IFNbeta were long-term survivors (>120 days; P < 0.001).

104 In long-term survivors (>150 days), an increase in anti-thi

105 althy volunteers and a group of "oldest old" long-term survivors (>85 years of age).

106 Long-term survivors had all received SCT either as first

107 All 10 long-term survivors had an MRD response.

108 portantly, CD4(+)CD25(+) Tregs obtained from long-term survivors had enhanced regulatory activity as

109 Asymptomatic long-term survivors had increased IPC number and functio

110 Long-term survivors had more pronounced T-cell expansion

111 Three long-term survivors had neurologic events or cytokine re

112 ence of the disease together with reports of long-term survivors has resulted in a more aggressive su

113 Eight long-term survivors have normal liver function without e

114 In long-term survivors, HCV infection is not associated wit

115 Among 142 long-term survivors, imatinib was the sole therapy admin

116 rk Heart Association functional class for 65 long-term survivors improved from 3.1 to 1.7.

117 onse against the tumor cell, we rechallenged long-term survivors in both murine models s.c. with the

118 graphic imaging was observed in 3 (50%) of 6 long-term survivors in comparison with 4 (8.9%) of 45 sh

119 wever, it is encouraging that there are five long-term survivors in our patient population.

120 owed by the administration of CCK-P produced long-term survivors in SCID (C.B.-17) mice bearing human

121 The six long-term survivors in the 21-day protocol accepted the

122 Two mice out of 15 long-term survivors in the BM+pDC group had virtually co

123 The only two long-term survivors in the CTL group showed moderate rej

124 nt experiments revealed that there were some long-term survivors in the group of mice [2/5 (66 and 12

125 oaches 80%, and there is a growing number of long-term survivors in the United States.

126 A large proportion of long-term survivors in the watchful-waiting group have n

127 fectious disease-derived peptides identified long-term survivors in two independent datasets, whereas

128 The 3 long-term survivors in whom tumor sterilization was achi

129 lly throughout the world, with the number of long-term survivors increasing rapidly.

130 igo dendrogliomas were overrepresented among long-term survivors independent of therapy.

131 expressing gp160 were identified for all six long-term survivors, indicating the presence of proviral

132 With many long-term survivors, it is important to evaluate long-te

133 Long-term survivors lost their mixed lymphocyte reactivi

134 transfer of lymphocytes from the DST-treated long term survivor (LTS) in a dose-dependent manner.

135 he presence of 19q loss was exclusive to the long-term survivor (LTS) group.

136 HIV-1 isolates from long-term survivors (LTS) were outcompeted by control st

137 We have previously identified a group of long-term survivors (LTS) who are clinically healthy and

138 To determine why these individuals, known as long-term survivors (LTS), remain healthy, the hematolog

139 ort-term survivors (STS; <or= 12 months) and long-term survivors (LTS; >or= 36 months), and explored

140 this study reports on the largest cohort of long-term survivors (LTSs) (>/=10 years) following a dia

141 To investigate African long-term survivors (LTSs) infected with non-subtype B h

142 Long-term survivors maintain normal hemodynamic function

143 Long-term survivors maintained peripheral CML response a

144 re leading to a rapidly increasing number of long-term survivors, many of whom are now adults.

145 A minority of long-term survivors may benefit from ongoing support.

146 hat influence this small number of unusually long-term survivors may provide important insight into t

147 Long-term survivors (mean, 10.0 +/- 5.3 years after trea

148 In addition, long-term survivor mice were protected against an RMA ly

149 s dreaded disease, the future needs of these long-term survivors must play an ever-increasing role in

150 median survival by an average 286%, with 26% long-term survivors (n = 117; P < 0.001).

151 Although long-term survivor nonprogressors had a significantly hi

152 The most striking attribute of long-term survivor nonprogressors was the detection of H

153 isolated some 14 months apart from a single long-term survivor of human immunodeficiency virus type

154 A potent neutralizing Fab fragment from a long-term survivor of simian immunodeficiency virus (SIV

155 e physician's evaluation and management of a long-term survivor of testicular cancer who was previous

156 Landmark analyses limited to long-term survivors of >/=1, >/=3, and >/=5 years demons

157 The mean cholesterol level of long-term survivors of 177 mg/dL was significantly highe

158 during intravenous adenosine hyperemia in 11 long-term survivors of a Mustard repair (age 18+/-5 year

159 sis) cancers; less is known regarding CVD in long-term survivors of adult-onset (>/= 40 years) cancer

160 Long-term survivors of ALCAPA repair demonstrate regiona

161 o determine the incidence of dyslipidemia in long-term survivors of ALL as well as the relationship b

162 Neurocognitive impairment in long-term survivors of ALL treated with cranial radiatio

163 he mean bone mineral density z scores of 309 long-term survivors of ALL were determined by quantitati

164 HD) continues to be the major problem in the long-term survivors of allogeneic hematopoietic stem cel

165 ulation after 10 years in certain subgroups, long-term survivors of autologous HCT continue to face c

166 Long-term survivors of bilateral ablations possess norma

167 study compared the quality of life (QOL) of long-term survivors of breast cancer and lymphoma who ha

168 compare the neuropsychologic functioning of long-term survivors of breast cancer and lymphoma who ha

169 er depression and anxiety are more common in long-term survivors of cancer compared with their spouse

170 s one of the leading causes of disability in long-term survivors of cancer.

171 arteriosclerosis is a major complication in long-term survivors of cardiac transplantation.

172 ns syndrome is a major problem for medium-to-long-term survivors of cardiothoracic transplantation.

173 ) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leu

174 , and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leu

175 Structural MRI of long-term survivors of childhood ALL demonstrated smalle

176 Long-term survivors of childhood ALL exhibit excess mort

177 problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemot

178 Results suggest long-term survivors of childhood ALL treated with CRT ar

179 We also evaluated a second population of 30 long-term survivors of childhood ALL; a fasting lipid an

180 Late sequelae are common in long-term survivors of childhood AML.

181 Long-term survivors of childhood and adolescent cancer w

182 Long-term survivors of childhood cancer are at increased

183 ON among long-term survivors of childhood cancer is rare.

184 Survivor Study (CCSS), a 26-center study of long-term survivors of childhood cancer that was diagnos

185 Sixty-two anthracycline-exposed long-term survivors of childhood cancer were studied at

186 A considerable proportion of the long-term survivors of childhood cancer with anthracycli

187 ) function and signs of focal fibrosis among long-term survivors of childhood cancer with the use of

188 In doxorubicin-treated long-term survivors of childhood cancer, enalapril-induc

189 n a clinically assessed ageing population of long-term survivors of childhood cancer.

190 and interpersonal relationship issues among long-term survivors of childhood cancer.

191 research and recommendations for the care of long-term survivors of childhood cancer.

192 e incidence of late cardiac complications in long-term survivors of childhood cancer.

193 reatment received, predicted adult weight in long-term survivors of childhood hematologic malignancie

194 These results suggest that adult long-term survivors of childhood HL are at risk for neur

195 Long-term survivors of childhood Hodgkin lymphoma (HL) a

196 ata documenting neurocognitive impairment in long-term survivors of childhood osteosarcoma.

197 Among older, long-term survivors of colorectal, breast, and prostate

198 how that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood mal

199 ic investigations, including those involving long-term survivors of Ebola.

200 t cardiovascular abnormalities are common in long-term survivors of HD who are treated at a young age

201 s is a prospective cohort study of 90 female long-term survivors of HD who had been treated > or = 8

202 a is the most prevalent epithelial cancer in long-term survivors of hereditary retinoblastomas caused

203 of microarray analyses in a larger cohort of long-term survivors of HGA.

204 ations on exercise capacity and mortality in long-term survivors of HL.

205 cond cancer is the leading cause of death in long-term survivors of Hodgkin disease (HD), with except

206 Long-term survivors of Hodgkin lymphoma (HL) are at an i

207 ociated with treatment decision regret among long-term survivors of localized prostate cancer.

208 latively infrequently reported outcome among long-term survivors of localized prostate cancer; howeve

209 provide the first description of the QOL of long-term survivors of lung cancer.

210 Twenty-eight long-term survivors of multisystem LCH (mean age, 15.1 y

211 Long-term survivors of multisystem LCH, particularly pat

212 nce significantly increases the mortality of long-term survivors of myeloablative allogeneic hematopo

213 dictors of heart failure (HF) development in long-term survivors of myocardial infarction (MI).

214 We examined change over time in QOL among long-term survivors of non-Hodgkin lymphoma and identifi

215 tudy examined changes in PTSD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and

216 tly explain the prevalence of skin cancer in long-term survivors of organ transplantation.

217 Long-term survivors of osteosarcoma are at risk for neur

218 leading cause of reduced quality of life in long-term survivors of paediatric brain tumours.

219 o both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clon

220 tional assays to identify T-cell antigens in long-term survivors of pancreatic cancer.

221 Our study population comprised 64,547 long-term survivors of PAYA cancers diagnosed between 19

222 Long-term survivors of pediatric and young adult (PAYA)

223 trial comparing enalapril to placebo in 135 long-term survivors of pediatric cancer who had at least

224 rvival and late mortality among contemporary long-term survivors of pediatric CNS tumor.

225 mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most

226 cross-sectional study to characterize DSA in long-term survivors of pediatric LTx and assess the impa

227 cent sexual HIV acquisition, or the aging of long-term survivors of perinatal HIV acquisition that oc

228 idence of biopsy-proven chronic rejection in long-term survivors of primary pediatric liver transplan

229 evaluate regional myocardial flow reserve in long-term survivors of repair of anomalous left coronary

230 Long-term survivors of seminoma treated with post-orchie

231 Long-term survivors of solid organ transplants have an 9

232 Long-term survivors of successfully treated Hodgkin's ly

233 talization for a cerebrovascular event among long-term survivors of teenage and young adult cancer.

234 In long-term survivors of testicular cancer, we observed a

235 rgical and catheter-based reinterventions in long-term survivors of the Fontan operation.

236 unction and impaired exercise performance in long-term survivors of the Mustard operation.

237 reserve in systemic right ventricles (RV) in long-term survivors of the Mustard operation.

238 associated with impaired clinical status in long-term survivors of TOF repair.

239 d in patients with severe TCAD compared with long-term survivors of transplantation without TCAD and

240 Long-term survivors of vertically acquired HIV in Africa

241 Long-term survivors of vertically acquired human immunod

242 We assessed the changes in HRQOL in long-term survivors of WHO grade I or II astrocytoma, ol

243 Four long-term survivors older than 16 years were included (3

244 These long-term survivors or long-term non-progressors have an

245 Ten of the 36 patients (28%) were long-term survivors (OS >/=30 months).

246 The eight long-term survivors received 5-6 x 10(9) hepatocytes and

247 Recipient long-term survivors received a second transplant, consis

248 Two long-term survivors received radiation therapy; one also

249 orary, in that T-cell-dependent responses in long-term survivors recovered to normal, and there was n

250 Despite the high cure rate of Wilms tumor, long-term survivors remain at risk of death from various

251 Six of the 10 long-term survivors remained relapse-free, including 4 w

252 Long-term survivors reported good overall functional sta

253 All long-term survivors required hormone replacement therapy

254 The majority of the long-term survivors retain fully functional bladders.

255 Most long-term survivors return to the care of their local he

256 Long-term survivors should be evaluated for the presence

257 Long-term survivors show a sequence of histologic resolu

258 Studies of long-term survivors show low-grade chronic inflammatory,

259 are doing well psychologically, a subset of long-term survivors show potentially serious mood distur

260 The three long-term survivors showed stable mixed hematopoietic ch

261 sistent with these results, splenocytes from long-term survivors specifically lysed the parental tumo

262 In particular, the long-term survivor subtype was characterized by increase

263 One long-term survivor suffered blindness consequent to the

264 who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bon

265 red microcephaly and regression of skills in long-term survivors suggests a neurodegenerative compone

266 sue and peripheral blood of two HIV-infected long-term survivors suppressed HIV replication at a low

267 The mean HIV-1 DNA levels were lower in the long-term survivors than in the progressors (P, 0.04).

268 appears to produce a higher CR rate and more long-term survivors than is achieved in patients with no

269 s, reduced AML tumor burden, and resulted in long-term survivors that sustained an anti-AML memory re

270 For long-term survivors, the incidence of cognitive deterior

271 tumor in the resected surgical specimen were long-term survivors; this suggests a benefit from esopha

272 o long-term survivorship and compared QOL in long-term survivors to that of age-matched women with no

273 The main causes of death among long-term survivors today are causes other than HL, alth

274 In long-term survivors, tumor shrinkage significantly corre

275 gen qualities promoting T-cell activation in long-term survivors, we discovered that these individual

276 Charges to produce a long-term survivor were significantly higher than for sh

277 These two long-term survivors were analyzed for in vitro evidence

278 Long-term survivors were assessed for cognitive and func

279 Long-term survivors were documented to be fully chimeric

280 For patients achieving remission, long-term survivors were found in those receiving either

281 who received marrow from allergic donors, 5 long-term survivors were identified.

282 Out of 43 patients operated, 23 long-term survivors were included.

283 e expression microarray profiles of HGA from long-term survivors were interrogated for discovery of s

284 Significant increases in lifespan and long-term survivors were noted in L1210 leukemia and B16

285 Long-term survivors were observed even after two unrelat

286 Long-term survivors were observed in all groups treated

287 nvelope glycoproteins cloned from four other long-term survivors were poorly processed and failed to

288 A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies w

289 Moreover, these long-term survivors were resistant to rechallenge with R

290 Long-term survivors were tested for tolerance by standar

291 expression in the lymphoid tissue of the two long-term survivors, were reduced compared with these pa

292 emia over a wide range of doses and produced long-term survivors when administered as a single i.p. b

293 Of the 99 long-term survivors who had no recurrent malignancy, 94

294 whereas the survival of 28 to 29 percent of long-term survivors, who avoid AIDS for 16 years or more

295 ildhood malignant brain tumor: However, many long-term survivors will have posttherapy growth hormone

296 subgroup of 6 miRNAs was able to distinguish long-term survivors with node-positive disease from thos

297 The identification and support of those long-term survivors with ongoing needs is a key challeng

298 Overall, 13 of 24 (54%) are long-term survivors with VeIP salvage chemotherapy.

299 cyte counts were substantially higher in the long-term survivors, with 3 (42.9%) of 7 having counts e

300 linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain un